Infectious Disease Diagnostics Market is expanding with the growing use of point-of-care testing. Portable diagnostic systems and rapid testing kits allow certain infections to be assessed closer to patients, helping improve access to testing in clinics, urgent care facilities, and locations with limited laboratory infrastructure.

The infectious disease diagnostics market was valued at US$ 38,366.38 million in 2022 and is expected to reach US$ 59,954.22 million by 2030, registering a CAGR of 5.7% from 2022 to 2030. Market growth is supported by the increasing need for early and accurate disease detection, rising awareness of infectious illnesses, and continued improvements in diagnostic technologies. These tests play an essential role in identifying pathogens, guiding treatment decisions, and supporting infection control across healthcare settings.

What is driving the market?

The infectious disease diagnostics market is driven by the growing demand for timely and reliable identification of bacterial, viral, fungal, and parasitic infections. Early diagnosis enables healthcare professionals to select appropriate treatments, reduce the risk of complications, and implement measures to limit the spread of infections. The continued need for diagnostic testing in hospitals, clinics, laboratories, and community healthcare settings supports demand for a broad range of testing solutions.

Get a Sample PDF- https://www.theinsightpartners.com/sample/TIPHE100001430

Technological advancements in molecular diagnostics, immunoassays, rapid antigen testing, and automated laboratory systems are also contributing to market development. These technologies can improve testing efficiency and help healthcare providers identify infectious agents more accurately. In addition, increasing attention to antimicrobial resistance and infection prevention is strengthening the role of diagnostic testing in treatment selection and patient management.

Which region leads?

Regional demand for infectious disease diagnostics is influenced by healthcare infrastructure, diagnostic laboratory capacity, disease prevalence, and access to testing services. North America offers important market opportunities through its established healthcare systems, advanced diagnostic technologies, and demand for timely infectious disease detection.

Europe also represents an important market, supported by clinical laboratory networks, public health initiatives, and the adoption of advanced diagnostic methods. Asia-Pacific has growth potential as healthcare infrastructure expands and access to diagnostic testing improves across developing markets. However, the leading region cannot be confirmed from the market size and CAGR figures provided alone.

Which segment leads?

The infectious disease diagnostics market includes several testing approaches, such as molecular diagnostics, immunodiagnostics, conventional culture methods, and other laboratory-based techniques. These approaches support the detection of pathogens and the identification of infections across different clinical settings.

Molecular diagnostic methods are valuable for identifying genetic material associated with infectious agents, while immunodiagnostic tests detect specific antigens or antibodies. Culture-based techniques also remain relevant for identifying certain microorganisms and supporting antimicrobial susceptibility testing. Applications span respiratory infections, bloodborne infections, gastrointestinal diseases, and other infectious conditions. The leading technology or application segment cannot be determined without detailed segment-level market data.

Which companies are prominent?

The infectious disease diagnostics market includes established diagnostic manufacturers and healthcare technology companies that provide testing products, laboratory systems, and diagnostic solutions. Key industry participants include Abbott Laboratories, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, ACON Laboratories Inc, Trinity Biotech Plc, DiaSorin SpA, Bruker Corp, AccuBioTech Co Ltd, and Danaher Corp.

These companies participate in different areas of infectious disease testing, including rapid diagnostic tests, molecular assays, immunoassays, and laboratory diagnostic platforms. Competition is shaped by test accuracy, turnaround time, ease of use, product availability, and compatibility with clinical laboratory workflows. Continued innovation and the development of solutions for diverse testing environments remain important competitive factors.

What is changing in 2026?

In 2026, the infectious disease diagnostics market continues to be influenced by the demand for faster testing, improved diagnostic accuracy, and more efficient laboratory workflows. Healthcare providers are increasingly focused on diagnostic solutions that help identify pathogens promptly and support appropriate treatment decisions.

Automation and advances in molecular testing are helping laboratories manage testing volumes and streamline diagnostic processes. There is also growing emphasis on antimicrobial resistance detection and the use of diagnostic results to guide targeted therapy. In addition, rapid testing solutions remain important in settings where access to centralized laboratories is limited. These developments are encouraging companies to improve test performance, accessibility, and operational efficiency.

What are the major investment opportunities?

Investment opportunities in the infectious disease diagnostics market include the development of rapid diagnostic tests, advanced molecular assays, automated laboratory systems, and tools for detecting antimicrobial resistance. Companies can also explore solutions designed for point-of-care testing, where accessible and timely results can support clinical decisions outside traditional laboratory settings.

Further opportunities exist in improving diagnostic access in underserved regions, expanding testing capabilities for emerging pathogens, and developing platforms that can identify multiple infectious agents. Partnerships with healthcare providers, laboratories, and public health organizations may help expand the adoption of diagnostic technologies. As the market is projected to reach US$ 59,954.22 million by 2030, innovation in accuracy, speed, accessibility, and laboratory efficiency is expected to remain central to market development.

Related Reports:

Molecular Diagnostics Market Growth, Analysis, and Forecast by 2030

Point-of-Care Testing Devices Market Size, Trends & Growth by 2034

About Us

The Insight Partners is a leading market research and consulting firm delivering actionable insights through in-depth industry analysis and strategic intelligence. The firm supports clients across various industries in making informed business decisions by providing comprehensive market forecasts, competitive assessments, and growth opportunities.

Contact Us

The Insight Partners
Email: sales@theinsightpartners.com
Phone: +1-646-491-9876
Website: www.theinsightpartners.com

Also Available in: Korean German Japanese French Chinese Italian Spanish